World News Insights
1-3 Minute Gist

Browse Articles or use Lyrarc's US patented "Groups" and "Links" for new insights. A Lyrarc Group of Articles on a topic gives insights into particular angles shown in the Group Title. A Lyrarc Link shows more specific insights for 2 articles.

All Topics Articles

LyrArc brings in selected articles from many of the world's top publications.

Articles are selected by experts and you can see the gist of the important articles.


New York Times Original article ›
New York Times Original article ›
New York Times Original article ›
New York Times Original article ›
New York Times Original article ›
New York Times Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
LyrArc Article Gist
Paul Davies says the leadership at Deutsche Bank is short sighted and cannot afford more slip ups or missteps following the U.S. New York Fed's examination. The examination revealed serious shortcomings in regulatory reporting and failure to correct them. As U.S. operations represent one fourth of its balance sheet this raises issues for the bank's overall financial position. Deutsche Bank has committed additional $1 billion in systems investment and staff to tackle this. Added problems he mentions are that Deutsche Bank lobbied against the Fed's proposal for foreign bank capital requirements even though it remains undercapitalized. The bank's leverage ratio at 3.4% is low and Davies says changes at the top are needed if further missteps occur.
Wall Street Journal Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
LyrArc Article Gist
Gilead Sciences sales of Sovaldi for Hepatitis C reach $3.5 billion in second quarter 2014. This would help double sales to $21-$23 billion in 2014. Issues are being raised about pricing of $1000 a day for 12 week course. At this pricing the new drug could reach only about 160,000 patients a year.
New York Times Original article ›
New York Times Original article ›
New York Times Original article ›
New York Times Original article ›

Support LyrArc

We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.

Support Lyrarc from as small as $1


Copyright © 2006 - 2026 Intelilinks LLC
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us